At a glance
ClinicalIndex Comparison Record- ✓Untreated stage IIIB NSCLC with pleural effusion
- ✓Untreated stage IV NSCLC
- ✓Recurrent after surgery if no prior radiation, chemotherapy, or immunotherapy (except palliative radiotherapy)
- ✓Age ≥18 years
- ✕Prior cancer history unless curative treatment completed ≥5 years before entry
- ✕Prior chemotherapy or immunotherapy for NSCLC (except brain/bone/lung radiation for palliative purposes)
- ✕Prior radiation to >25% of bone marrow for any previous cancer
- ✕Uncontrolled intercurrent illness
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trail of Carboplatin and Gemcitabine Untreated Stage IIIB-pleural Effusion and Stage IV Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Dexamethasone, and 1 other intervention for Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer. Completed, enrolled 60 participants across 7 sites.
Detailed Summary
The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer. This study will determine if dexamethasone, when given before standard chemotherapy will increase the cancer fighting effects and reduce the side effects of chemotherapy.
Study Details
Timeline
Interventions
Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
16 mg bid for 4 days prior to each chemotherapy start.
AUC 6.0 intravenously over 30 minutes on day 5.